(CercleFinance.com) – Genfit announced on Monday the acquisition of the Swiss biopharmaceutical company Versantis with a view to enriching its portfolio of products in liver diseases.
In a press release, the company explains that the operation is part of its strategy to become a world leader in ACLF, a pathology also known as acute decompensation of cirrhosis.
This disease, associated with a high short-term mortality (ranging from 23% to 74% within 28 days, depending on the severity of the diagnosis), leads to some 137,000 American patients each year being hospitalized, with very few treatment options available. their disposal.
Genfit talks about ‘another essential step’ in the execution of its strategy, with the integration of a clinical phase compound supported by promising phase 1b and preclinical data.
The terms of the agreement include an upfront payment of 40 million Swiss francs (about 41 million euros), as well as an aggregate of 65 million francs.
The contract also provides for potential additional payments conditional on the achievement of regulatory and clinical milestones, and one-third of the net proceeds from the potential sale of the priority review voucher should it be granted by the US FDA.
The title Genfit reacted little to this announcement Monday morning on the Paris Stock Exchange, posting a limited gain of 0.3% after about an hour of trading.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
Are you following this action?
Receive all the information about GENFIT in real time: